

Remarks

Applicant submits the foregoing Amendment to the Claims; Entry of the Amendment and favorable consideration thereof is respectfully requested.

Enablement

The Examiner has rejected claims 1-3, 10-12, 17, 18, 21, and 26-27 under 35 U.S.C. §112, first paragraph, as not being enabled by the specification, on the grounds that the specification is enabling for "an *in vitro* method of delivering a peptide to a cell expressing GM-1 ganglioside receptors on the surface of the cell" using the specified mutant B-subunits of ETxB and CtB, but that claims read on both *in vitro* and *in vivo* methods.


In response, Applicant has amended claims 1, 17, and 21 to specify *in vitro* methods of delivering a peptide using the specified mutant B-subunits of ETxB and CtB.

As the amended claims specify *in vitro* methods which the Examiner has indicated to be enabled by the specification, it is respectfully submitted that the rejection under 35 U.S.C. §112, first paragraph should be withdrawn.

Sine there are no other remaining issues, issuance of a Notice of Allowance is requested.

Respectfully submitted,

February 7, 2008



Stephen P. McNamara, Registration No. 32,745
Attorney for Applicant
ST. ONGE STEWARD JOHNSTON & REENS LLC
986 Bedford Street
Stamford, CT 06905-5619
Tel. (203) 324-6155